Champions Oncology Expands Integrated Radiopharmaceutical Development Platform with In-House SPECT/CT Imaging

Rhea-AI Summary

Champions Oncology (NASDAQ: CSBR) announced an expansion of its integrated radiopharmaceutical development platform with new in-house SPECT/CT imaging capabilities at its U.S.-based facility. The enhancement connects longitudinal in vivo imaging of radiopharmaceutical uptake with terminal biodistribution, efficacy readouts and clinically annotated patient-derived xenograft (PDX) tumor biology in a single workflow.

The platform now combines high-resolution SPECT/CT using the Molecubes γ-X CUBE micro-SPECT/CT system, access to PDX and CDX oncology models, integrated radiolabeling services, and a broad panel of alpha- and beta-emitting isotopes, including newly added Radium-224/Lead-212 Generator and Terbium-161, supported by expert study design and data interpretation.

Positive

• Addition of in-house SPECT/CT imaging integrates longitudinal uptake, biodistribution and efficacy in one workflow
• Access to clinically annotated PDX and CDX models supports model selection by tumor type and target expression
• Expanded isotope panel with Radium-224/Lead-212 Generator and Terbium-161 broadens radiopharmaceutical modalities
• Integrated radiolabeling and study execution centralize preclinical radiopharmaceutical development with a single partner

Negative

• None.

Market Context

ATRA declined 2.09% and OVID declined 3.96% in the current peer data, while CSBR's pre-headline move...

Analysis

ATRA declined 2.09% and OVID declined 3.96% in the current peer data, while CSBR's pre-headline move was 1.32%. The divergence makes quantified study outcomes and commercial metrics important follow-up points.

Key Figures

New isotopes: 2 new isotopes

1 metrics

New isotopes 2 new isotopes Expanded radiopharmaceutical development capabilities

Historical Context

5 past events · Latest: Jul 27 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 27	Annual earnings report	Negative	-8.8%	Operating loss and lower EBITDA accompanied record annual oncology revenue
Jul 20	Earnings date notice	Neutral	+0.0%	Company scheduled fourth-quarter and year-end financial results announcement
Apr 09	AACR data presentation	Positive	-4.6%	Company announced eight posters covering predictive oncology response and resistance research
Mar 30	Board appointment	Positive	+1.7%	Brian Alexander joined the board to support data-driven oncology strategy
Mar 12	Quarterly earnings report	Positive	+6.3%	Study service revenue growth accompanied quarterly adjusted EBITDA and cash disclosure

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The selected history showed mixed reactions, including a -8.75% earnings response, a +6.27% earnings response, and a -4.64% response to AACR presentation news.

Key Terms

biodistribution, spect/ct, patient-derived xenograft, radioligand therapies, +1 more

5 terms

biodistribution medical

"connect longitudinal radiopharmaceutical uptake with biodistribution, efficacy"

Biodistribution is the map of where a drug, vaccine, or diagnostic agent travels and accumulates inside the body after administration. Investors care because where a product ends up affects how well it works, what side effects it may cause, and whether regulators will approve it—similar to tracking dye in a plumbing system to find leaks or blockages; unexpected destinations can raise safety, cost, and market-adoption risks.

spect/ct technical

"new in-house SPECT/CT imaging capabilities"

SPECT/CT is a medical imaging scan that combines two types of pictures: one that shows how organs and tissues are working (SPECT) and one that shows detailed anatomy (CT), layered together like a weather radar over a street map. For investors, it matters because clearer, combined images can improve diagnosis, guide treatment choices, and drive demand for imaging equipment, radiopharmaceuticals, and clinical services—factors that influence healthcare revenues and reimbursement trends.

patient-derived xenograft medical

"clinically annotated patient-derived xenograft (PDX) models"

A patient-derived xenograft (PDX) is a laboratory model created by implanting a tumor or diseased tissue taken directly from a human patient into an animal host that can support its growth. Because PDX models tend to mirror how a human tumor behaves and responds to treatments better than simple cell cultures, investors view their use as a stronger signal that preclinical drug results may translate to patients, lowering development risk much like a full-scale dress rehearsal raises confidence before opening night.

radioligand therapies medical

"including radioligand therapies, antibody-radionuclide conjugates"

Radioligand therapies are treatments that combine a molecule that seeks out specific disease cells with a small radioactive particle, delivering radiation directly to those cells much like a guided missile delivers a warhead to a target. They matter to investors because successful therapies can create new, high-value products and revenue streams while also carrying clinical, regulatory and manufacturing risks that can dramatically affect a company’s valuation and future prospects.

theranostic medical

"and theranostic approaches"

A theranostic is a single medical approach or agent that combines diagnosis and treatment—using a test or imaging step to find patients likely to benefit, then delivering a targeted therapy tied to that same marker. For investors, theranostics can speed development, lower the chance of failed trials and concentrate sales on the right patients, like a smart key that both locates the correct lock and opens it, potentially improving clinical and commercial success.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

New molecular imaging capabilities connect longitudinal radiopharmaceutical uptake with biodistribution, efficacy and clinically annotated PDX tumor biology in a single, U.S.-based workflow

HACKENSACK, NJ / ACCESS Newswire / September 1, 2026 / Champions Oncology, Inc., a leading provider of translational oncology research solutions, today announced the expansion of its integrated radiopharmaceutical development platform with new in-house SPECT/CT imaging capabilities.

This capability extends Champions' existing radiopharmaceutical services across radiolabeling, biodistribution, efficacy and clinically relevant oncology models. Researchers can now longitudinally visualize and quantify radiopharmaceutical uptake in vivo, and connect those findings with terminal biodistribution, therapeutic response and the molecular characteristics of the tumor model.

This integrated approach is particularly powerful when applied to Champions' extensive portfolio of clinically annotated patient-derived xenograft (PDX) models, enabling sponsors to evaluate not only where a radiopharmaceutical localizes, but how uptake relates to target expression, tumor biology and therapeutic response.

The integrated platform enables the creation of richer translational datasets that can support increasingly predictive approaches to radiopharmaceutical development, including improved model selection, biomarker identification, and interpretation of therapeutic response.

"Imaging adds an important dimension we didn't have before" said Denis Beckford-Vera, Ph.D., Head of Radiochemistry and Radiopharmacology at Champions Oncology. "We can follow an agent longitudinally in the same model, quantify its distribution across tumor and biologically relevant tissues, and then connect those observations with efficacy and tumor biology. That combination provides developers with a much richer understanding of candidate performance than any individual readout can provide on its own."

Champions Oncology's expanded radiopharmaceutical development capabilities include:

• Access to clinically annotated PDX and CDX oncology models, enabling model selection based on tumor type, target expression and molecular characteristics

• In-house high-resolution SPECT/CT imaging using the Molecubes γ-X CUBE micro-SPECT/CT system, enabling longitudinal imaging combined with terminal biodistribution

• A broad range of therapeutic alpha- and beta-emitting isotopes, with the addition of two new isotopes: Radium-224/Lead-212 Generator and Terbium-161

• Integrated radiolabeling services encompassing isotope planning and handling, radiolabeling, quality control and study execution

• Expert study design, data interpretation and scientific support from radiochemistry, radiopharmacology and oncology leaders

"Our vision is to make radiopharmaceutical development more predictive. Connecting in vivo imaging with the depth of our oncology models lets sponsors see not just where an agent localizes, but how disease responds, and decide earlier, which candidates are worth advancing." commented Rob Brainin, Ph.D., CEO of Champions Oncology.

The expanded platform supports radiopharmaceutical development across multiple therapeutic strategies, including radioligand therapies, antibody-radionuclide conjugates and theranostic approaches, while allowing programs to progress through an integrated preclinical workflow with a single scientific partner.

For more information about Champions Oncology's radiopharmaceutical development services and SPECT/CT imaging capabilities, visit https://www.championsoncology.com/radiopharmaceutical.

Media Inquiries:

Gavin Cooper
Vice President, Global Marketing
gcooper@championsoncology.com

Website: https://www.championsoncology.com/
Facebook: https://www.facebook.com/championsoncology/
LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/
Twitter: @ChampionsOncol1
Instagram: https://www.instagram.com/championsoncology/

SOURCE: Champions Oncology, Inc.

View the original press release on ACCESS Newswire

FAQ

What did Champions Oncology (CSBR) announce on September 1, 2026 about SPECT/CT imaging?

Champions Oncology announced new in-house SPECT/CT imaging capabilities integrated into its radiopharmaceutical development platform. According to Champions Oncology, this connects longitudinal in vivo imaging with biodistribution, efficacy and tumor biology in a single U.S.-based workflow, supporting more informative preclinical radiopharmaceutical studies for sponsors.

How does the new SPECT/CT platform benefit radiopharmaceutical development for CSBR sponsors?

The platform enables sponsors to visualize and quantify radiopharmaceutical uptake over time in vivo and link it to biodistribution, efficacy and tumor biology. According to Champions Oncology, this integration can support improved model selection, biomarker identification and interpretation of therapeutic response in radiopharmaceutical programs.

What models are available in Champions Oncology’s expanded radiopharmaceutical platform (CSBR)?

Champions Oncology offers access to clinically annotated PDX and CDX oncology models within its expanded platform. According to Champions Oncology, sponsors can select models based on tumor type, target expression and molecular characteristics, enabling evaluation of how radiopharmaceutical uptake relates to tumor biology and therapeutic response.

Which new isotopes were added to Champions Oncology’s radiopharmaceutical services for CSBR?

The company added a Radium-224/Lead-212 Generator and Terbium-161 to its panel of therapeutic isotopes. According to Champions Oncology, these join a broad range of alpha- and beta-emitting isotopes available for radioligand therapies, antibody-radionuclide conjugates and theranostic approaches in preclinical studies.

What specific SPECT/CT system does Champions Oncology use in its CSBR platform?

Champions Oncology uses the Molecubes γ-X CUBE micro-SPECT/CT system for high-resolution in-house imaging. According to Champions Oncology, this enables longitudinal SPECT/CT imaging combined with terminal biodistribution assessment, generating richer translational datasets for radiopharmaceutical development within a single integrated workflow.

How integrated are radiolabeling and study services in Champions Oncology’s CSBR radiopharmaceutical platform?

Champions Oncology provides integrated radiolabeling services covering isotope planning, handling, radiolabeling, quality control and study execution. According to Champions Oncology, these services are combined with expert study design, data interpretation and oncology support, allowing sponsors to progress programs with one scientific partner.